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MINIMAL RESIDUAL DISEASE PRIOR TO AUTOLOGOUS STEM CELL
TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOGENOUS LEUKE-
MIA AS A PREDICTOR OF RELAPSE
Rojas, A.M.1, Song, S.X.2, Corliss, A.1, Truell, J.2, Paquette, R.L.1,
Schiller, G.J.1, Territo, M.C.1 1 UCLA Medical Center, Los Angeles,
CA; 2 UCLA Medical Center, Los Angeles, CA.
The level of minimal residual disease (MRD) after consolidation
has been reported in the past as being a strong predictor of relapse in
patients treated with standard chemotherapy. We evaluated the
presence of MRD in our adult patients with acute myelogenous leu-
kemia (AML) after consolidation and just prior to autologous stem
cell transplant. A total of 47 patients underwent autologous stem
cell transplant for AML from June, 2002 through December,
2004. All patients were in first complete remission and had achieved
this remission after induction chemotherapy using cytarabine and
idarubicin, with the standard 71 3 regimen followed by one course
of consolidation with mitoxantrone and high dose cytarabine. All
patients had bone marrow obtained 2–4 weeks prior to transplant
and were in complete remission as defined by morphology. Data
were available on 42 of these patients to look for MRD by multi-
parametric flow cytomety at a sensitivity level of 0.5 to 1%. Out
of these 42 patients, 15 (36%) had documented MRD detected on
bone marrow biopsy prior to transplant. All 15 of the patients
have relapsed and died. Of the 27 patients who did not have evi-
dence of MRD going into transplant, 14 have relapsed. Thus despite
lack of evidence of MRD, using our past techniques, relapse was
seen in 52% of these patients. At this time we are in the process
of evaluating a subsequent group of patients who underwent autol-
ogous stem cell transplant using a more sensitive assay for MRD. In
conclusion, in spite of morphologic complete remission, evidence of
MRD after consolidation and prior to autologous stem cell trans-
plant was predictive of relapse. In the future, alternative treatment
approaches should be considered for such patients.156
TREATMENT OF MYELOID MALIGNANCIES IN ELDERLY PATIENTS WITH
FLUDARABINE AND TARGETED BUSULFAN (t-Bu) AND ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Fernandez, H.F., Henao-Uribe, A.M., Poling, W.H., Chavez, J.C.,
Alsina, M., Ayala, E., Field, T., Kharfan-Dabaja, M., Perez, L.,
Raychaudhuri, J., Ochoa-Bayona, L., Anasetti, C. H Lee Moffitt Cancer
Center and Research Institute, Tampa, FL.
Despite the poor prognosis of elderly patients with standard che-
motherapy, concerns with intensive conditioning regimens have lim-
ited the use of allogeneic HCT in this population. Reduced intensity
regimes have emerged as an option for these patients. We treated
twenty patients over the age of 60 with fludarabine and targeted bu-
sulfan (t-Bu). The median busulfan AUC received was 5244 mmol/
min. Graft versus host disease (GVHD) prophylaxis consisted in ta-
crolimus and methotrexate (75%) and tacrolimus and mycophenolate
mofetil (25%). Median age was 64.8 (60–69) years. Eleven were male
(55%) and nine female (45%). Six patients (30%) had de novo AML,
ten (50%) secondary AML and four (20%) high risk MDS. Five pa-
tients (25%) had high-risk disease in first complete remission
(CR1) and five (25%) had AML in second complete remission
(CR2). Ten patients were not in remission at the time of transplant.
Donor sources included six (30%) HLA-matched siblings, 13
(65%) matched unrelated and one (5%) mismatched unrelated donor.
A high Sorror Comorbidity Index (.3 points) was found in 35% of
patients. Acute GVHD occurred in all the patients (65% Grade I/
II, 35% grade III/IV). The median follow-up of survivors was 731
days (113–11491). Non-relapse mortality was 10%. Relapse rate at
365 days was 45%. Disease-free (DFS) and overall survival (OS) at
365 days were 50.91/-12% and 61.301/-12% respectively.
Conclusion: Given the sub-optimal results of standard chemo-
therapy in this patient population and the low transplant related
mortality and encouraging OS seen in our cohort, targeted RIC al-
logeneic HSCT should be considered as a feasible alternative in pa-
tients older than 60 years with high risk MDS/AML. Further study
in this group is warranted.157
THERAPEUTIC CHOICES IN PATIENTS WITH PH1 (1) CHRONIC MYE-
LOGENOUS LEUKEMIA LIVING IN DEVELOPING COUNTRIES IN THE
TYROSINE KINASE INHIBITORS (TKI) ERA: STEM CELL TRANSPLANTA-
TION OR TKI?
Ruiz-Arguelles, G.J.1,2, Tarin-Arzaga, L.C.3, Gonzalez-
Carrillo, M.L.2, Gutierrez-Riveroll, K.I.1, Rangel-Malo, R.2, Gutier-
rez-Aguirre, C.H.3, Cantu-Rodriguez, O.G.3, Gomez-Almaguer, D.3,
Giralt, S.4 1 Centro de Hematologia y Medicina Interna de Puebla, Pue-
bla, Mexico; 2 Laboratorios Clinicos de Puebla, Puebla, Mexico; 3 Hospital
Universitario, Monterrey, Nuevo Leon, Mexico; 4 MD Anderson Cancer
Center, Houston, TX.
Seventy two patients with Ph1 (1) chronic myelogenous leuke-
mia (CML) in a first chronic phase were followed during a 6-year
period in two different institutions in Mexico. Twenty two of
them were given a reduced-intensity allogeneic stem cell transplan-
tation, whereas 50 were treated with a tyrosine kinase inhibitor
(TKI), mainly imatinib mesylate. The two groups were balanced
in their salient features and the overall results of the treatment
were statistically similar: The six-year overall survival (SV) for pa-
tients given an allograft was 77% and for patients given a TKI
was 84% (p NS); whereas the median survival for both groups has
not been reached, being above 71 and 90 months respectively (p
NS). Most of the patients (91%) who were allografted elected this
treatment because they were unable to afford the treatment with
a TKI, whereas most of those treated with a TKI (84%) were given
the treatment through institutions devoted to support the treatment
of such individuals; only 16% were able to afford the treatment with
TKI. The median cost of each allograft was 18 000 USD, an amount
which is useful to afford 180 days of treatment with imatinib (400
mg/day) in Mexico. Despite the fact that drug treatment is superior
to allografting as first-line therapy in CML in chronic phase in de-
veloped countries, stem cell transplantation has still a relevant role
in circumstances of limited resources. Cost considerations favor al-
logeneic stem cell transplantation as a one-in-a-life-time procedure
in which lifelong drug treatment with an expensive drug represents
an excessive burden on resources.158
RELAPSE OF ACUTE MYELOID LEUKMIA AFTER ALLOGENEIC STEM-
CELL TRANSPLANTATION (SCT)WITHMYELOABLATIVE CONDITIONING
IS ASSOCIATED WITH LONGER SURVIVAL THAN RELAPSE AFTER RE-
DUCED-INTENSITY CONDITIONING (RIC)
Shimoni, A., Hardan, I., Shem-Tov, N., Rand, A., Ribakovsky, E.,
Yerushalmi, R., Nagler, A. Chaim Sheba Medical Center, Tel-
Hashomer, Israel.
Relapse of AML/MDS after allogeneic SCT is associated with
poor outcome. A subset of patients (pts) can be salvaged with DLI
or with a second SCT. It was previously speculated that pts given
RIC may have a better chance to be salvaged than pts failing
high-dose conditioning. We retrospectively analyzed results of
171 SCTs for AML/MDS with iv busulfan (ivBu)-based regimens.
58 pts were eligible for myeloablative conditioning and were given
standard ivBuCy. 57 were given RIC consisting of fludarabine (F)
and ivBu (FB2, 6.4 mg/kg) and 56 were given a modified myeloabla-
tive conditioning consisting of F and full-dose ivBu (FB4, 12.8 mg/
kg). Median age was 40 (17–64), 60 (43–75) and 52 (18–66) years,
respectively (p \ 0.001). 56% had active leukemia at SCT and
47% had unrelated donors with no difference between the regi-
mens. With a median follow-up of 31 months (4–90), 70 pts re-
lapsed, 20 after BuCy, 25 after FB2, and 25 after FB4, cumulative
incidence 38%, 49% and 48%, respectively (p5NS). The median
time to relapse was 5.3 (1–59), 3.4 (1–34) and 2.7 (1–30) months, re-
spectively (p5NS); 65%,60% and 64% of all relapses occurred
within 6 months of SCT, while 20%, 12% and 8% occurred after
more than 2 years, respectively (p5NS). 25 pts were treated with
immune-suppression withdrawal alone, 12 were given DLI with
or without preceding low-dose chemotherapy, 33 were given inten-
sive therapy either salvage chemotherapy followed by mobilized
DLI (n 5 24) or a second SCT (n 5 9, 5 from a different donor).
Treatment types were not significantly different among the
